iSpecimen (NASDAQ:ISPC) Releases Earnings Results

iSpecimen (NASDAQ:ISPC) posted its quarterly earnings results on Friday. The company reported ($0.98) earnings per share (EPS) for the quarter, FiscalAI reports. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.The business had revenue of $0.15 million during the quarter.

iSpecimen Stock Performance

Shares of NASDAQ:ISPC traded down $0.05 during midday trading on Friday, reaching $2.25. The company had a trading volume of 38,846 shares, compared to its average volume of 62,931. iSpecimen has a 1-year low of $1.77 and a 1-year high of $127.20. The firm has a market cap of $3.42 million, a price-to-earnings ratio of -0.04 and a beta of 1.66. The company has a fifty day simple moving average of $2.39 and a two-hundred day simple moving average of $5.79.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned approximately 0.30% of iSpecimen as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ISPC. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, iSpecimen presently has a consensus rating of “Sell”.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.